Targeting TNF alpha as a novel strategy to enhance CD8+ T cell-dependent immune response in melanoma?

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Bertrand, Florie ^a,b   Rochotte, Julia ^a,b,c   Colacios, Céline ^a,b,c   Montfort, Anne ^a,b,d   Andrieu Abadie, Nathalie ^a,b   Levade, Thierry ^a,b,c   Benoist, Hervé ^a,b,c   Ségui, Bruno ^a,b,c  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Equipe 'Labellisée LA LIGUE CONTRE LE CANCER 2013'   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; High endothelial venules; Melanoma; T lymphocytes; TNF; Tumor infiltrating CD8+ Lymphocytes

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DEATH; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MELANOMA; NONHUMAN; PROTEIN HOMEOSTASIS; SIGNAL TRANSDUCTION;

EID: 84954441168     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1068495     Document Type: Article

References (10)

1. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007; 179:154-61; PMID:17579033; http://dx. doi. org/10. 4049/jimmunol. 179. 1. 154
2. Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012; 122:4094-104;PMID:23064360; http://dx. doi. org/10. 1172/JCI64115
3. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412-6; PMID:23051752; http://dx. doi. org/10. 1038/nature11538
4. +T cell-dependent immunity in experimental melanoma. Cancer Res 2015; 75(13):2619-28; PMID:25977337; http://dx. doi. org/10. 1158/0008-5472. CAN-14-2524
5. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377:348-51; PMID:7566090; http://dx. doi. org/10. 1038/377348a0
6. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, Garrido I, Girard JP. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 2012; 1:829-39; PMID:23162750; http://dx. doi. org/ 10. 4161/onci. 20492
7. Martinet L, Garrido I, Girard JP. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology 2012; 1:789-90; PMID:22934284; http://dx. doi. org/10. 4161/onci. 19787
8. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, NakadaM, Corringham RE et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-a inhibitor, in patients with advanced cancer. Ann Oncol 2008; 19:1340-6; PMID:18325912; http://dx. doi. org/10. 1093/annonc/mdn054
9. Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol 2013; 191:2217-25; PMID:23904171; http://dx. doi. org/10. 4049/jimmunol. 1300538
10. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012; 18:2326-35; PMID:22355009; http://dx. doi. org/10. 1158/ 1078-0432. CCR-11-2515